Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Profitability
This table compares Lisata Therapeutics and Sagimet Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -116.08% | -90.55% |
| Sagimet Biosciences | N/A | -31.96% | -30.57% |
Risk and Volatility
Lisata Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.43, meaning that its share price is 243% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Lisata Therapeutics and Sagimet Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Sagimet Biosciences | 2 | 1 | 9 | 0 | 2.58 |
Sagimet Biosciences has a consensus target price of $26.63, indicating a potential upside of 170.40%. Given Sagimet Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Lisata Therapeutics.
Valuation and Earnings
This table compares Lisata Therapeutics and Sagimet Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | $170,000.00 | 65.44 | -$16.59 million | ($1.64) | -0.63 |
| Sagimet Biosciences | $2.00 million | 306.14 | -$51.04 million | ($1.28) | -7.70 |
Lisata Therapeutics has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Sagimet Biosciences beats Lisata Therapeutics on 11 of the 13 factors compared between the two stocks.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
